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Abstract 
Background: A new group of oral anticoagulants (dabigatran, rivaroxaban, apixaban and edoxaban) with clear 
advantages over classic dicoumarin oral anticoagulants (warfarin and acenocoumarol) has been developed in re-
cent years. Patients being treated with oral anticoagulants are at higher risk for bleeding when undergoing dental 
treatments.  
Material and Methods: A literature search was conducted through April 2016 for publications in the ISI Web of 
Knowledge, PubMed and Cochrane Library using the keywords “dabigatran”, “rivaroxaban”, “apixaban”, “edoxa-
ban”, “new oral anticoagulants”, “novel oral anticoagulants”, “bleeding” and “dental treatment”. 
Results: There is no need for regular coagulation monitoring of patients on dabigatran therapy. Whether or not to 
temporarily discontinue dabigatran must be assessed according to the bleeding risk involved in the dental procedure 
to be performed.
Conclusions: The number of patients under treatment with new oral anticoagulants will increase in the coming 
years. It is essential to know about the pharmacokinetics and pharmacodynamics of new oral anticoagulants and 
about their interactions with other drugs. It is necessary to develop clinical guidelines for the perioperative and 
postoperative management of these new oral anticoagulants in oral surgical procedures, and to carefully evaluate 
the bleeding risk of dental treatment, as well as the thrombotic risk of suppressing the new oral anticoagulant.
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Introduction
The number of patients under treatment with anticoagu-
lant and antiplatelet drugs that require dental treatment 
has grown in recent years, so that there are many anti-
coagulated patients in our area. Oral anticoagulants and 
antiplatelet drugs are used for primary and secondary 
prevention of venous thromboembolic diseases (1).
Vitamin K antagonist anticoagulant drugs have been wi-
dely used for the treatment of nonvalvular atrial fibri-
llation. Atrial fibrillation is the first cause of embolism, 
regardless of whether it is associated to valve disease 
or not. For decades, it has been standardly treated with 
dicoumarin anticoagulants, mainly acenocoumarol and 
warfarin (2). Their therapeutic window is narrow and 
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patients require regular International Normalized Ratio 
(INR) monitoring. Vitamin K antagonist drugs show 
many interactions with other drugs and with certain 
food.
The ideal oral anticoagulant should be safer and more 
effective than classic oral anticoagulants. In recent 
years, research in the area of pharmacology has focused 
on the development of new oral anticoagulants with a 
wide therapeutic window, few drug-drug and food-drug 
interactions, low intraindividual variability and no need 
for regular and systematic monitoring.  
The four new oral anticoagulants that have been deve-
loped and are currently marketed are dabigatran (Pra-
daxa®), rivaroxaban (Xarelto®), apixaban (Eliquis®) 
and edoxaban (Lixiana®). Rivaroxaban, apixaban and 
edoxaban are direct Factor Xa inhibitors, while dabiga-
tran is a direct thrombin inhibitor (3).
The efficacy of dabigatran in the treatment of nonvalvu-
lar atrial fibrillation was assessed in 2009 in the RE-LY 
study, which compared the use of warfarin versus dabi-
gatran using a sample of 18113 patients with nonvalvu-
lar atrial fibrillation. The study showed a reduction in 
cardiovascular events in patients treated with dabigatran 
as compared to those taking warfarin (4,5).
According to the European Medicines Agency (EMA), 
the dose of dabigatran for the prevention of stroke and 
systemic embolism in patients with nonvalvular atrial fi-
brillation is between 110 and 150 mg taken orally every 
12 hours (6).
Dabigatran exerts its anticoagulant effect through plas-
matic binding to thrombin, thus deactivating it. It is a 
potent, selective, reversible and competitive thrombin 
inhibitor, and its possibility to reach the clot and deacti-
vate the thrombin is one of the advantages of these new 
oral anticoagulants.  
By inhibiting thrombin, dabigatran reduces the forma-
tion of fibrin, inhibits thrombin-mediated platelet activa-
tion and reduces fibrinolysis inhibition (7).
After oral administration of dabigatran etexilate, it is 
quickly metabolized to its active form by esterases in the 
intestine. Plasma concentrations peak within 2 hours of its 
administration and decrease by half after 12 hours (8).
Table 1 shows the pharmacological characteristics of 
new oral anticoagulants (9).
A shortcoming that was noticed during the initial stages 
of the development of these new drugs was the absen-
ce of antidotes to reverse their anticoagulant effect in 
Plasma protein binding Bioavailability Half-life Renal excretion
Dabigatran 3% 6% 15 hours 80%
Rivaroxaban 90% 80% 11 hours 33%
Apixaban 87% 50% 12 hours 25%
Edoxaban 54% 50% 10 hours 35%
Table 1. Pharmacological characteristics of new oral anticoagulants.
comparison with classic Vitamin K antagonist anticoa-
gulant drugs. In recent years, substances able to reverse 
the effect of new oral anticoagulants have been develo-
ped, among them idarucizumab (specific reversal agent 
of the anticoagulant effect of dabigatran), adexanet alfa 
and ciraparantag. In October 2015, the Food and Drug 
Administration (FDA) approved the marketing of idaru-
cizumab (Praxbind®) as an antidote to the anticoagulant 
effect of dabigatran. Idarucizumab rapidly and comple-
tely reversed (within minutes) the anticoagulant activity 
of dabigatran in 88 to 98 % of patients in an initial cli-
nical study. The approval of idarucizumab will substan-
tially influence the approach to haemorrhagic complica-
tions related to dabigatran. It is worth noting that there 
is currently scarce clinical experience in the use of these 
new substances (10).
In economic terms, the cost of treatment with dabigatran 
is higher than with warfarin or acenocoumarol (11).
Material and Methods
The aim of this paper is to contribute to the discussion 
on how to approach patients taking dabigatran, before, 
during and after dental treatment in light of the more 
recent knowledges.
In the present contribution we offer an exhaustive review 
of the literature found in the ISI Web of Knowledge, 
PubMed and Cochrane Library in April 2016, including 
articles published in the last 10 years. The words used 
were “dabigatran”, “rivaroxaban”, “apixaban”, “edoxa-
ban”, “new oral anticoagulants”, “novel oral anticoagu-
lants”, “bleeding” and “dental treatment” with the “and” 
boolean operator.
Results
-Analytical tests:
Regular routine monitoring of the anticoagulant effect 
of new oral anticoagulants is not required, although it 
is necessary to be aware of their anticoagulant effect in 
the event of bleeding before starting invasive treatments. 
The effects of dabigatran can be quantified through di-
fferent coagulation tests. New oral anticoagulants affect 
classic analytical tests in a dose-dependent manner. This 
entails a change of perspective in laboratory tests related 
to the perioperative management of new oral anticoagu-
lants with regard to classic oral anticoagulants (12).
The ecarin clotting time, thrombin time and diluted 
thrombin time are sensitive to dabigatran plasma con-
J Clin Exp Dent. 2017;9(2):e289-93.                                                                                                                                                            Implications of dabigatran in dental treatments
e291
centrations. Prothrombin time and activated partial 
thromboplastin time show low sensitivity to dabigatran. 
The determination of anti-Xa concentrations is the most 
specific test to measure dabigatran plasma concentra-
tions (13-16).
-Dental management:
Patients under treatment with oral anticoagulants are at 
higher risk for bleeding when undergoing invasive den-
tal treatments (17).
It may be necessary to temporarily discontinue dabiga-
tran depending on the risk for bleeding involved in the 
dental treatment to be carried out and the patient’s renal 
function. Patients being treated with oral anticoagulants 
who have impaired renal function are at higher risk for 
bleeding (the fact that approximately 80% of dabigatran 
is excreted via the kidneys should be taken into account) 
(18,19).
Several studies have proved that the risk for bleeding 
of patients under treatment with new oral anticoagulants 
is similar to that of patients being treated with warfarin 
when International Normalized Ratio (INR) values are 
between 2 and 3 (20,21).
Based on the risk for bleeding involved, dental treatments 
can be classified into procedures with a low bleeding risk 
and procedures with medium or high bleeding risk.
-Perioperative management in dental procedures with 
low bleeding risk:
Temporary discontinuation of dabigatran is not neces-
sary prior to invasive dental procedures with low blee-
ding risk, which include simple exodontia, oral surgery 
of up to 45 minutes and periodontal surgery with mini-
mal bleeding risk (22-25). Hemostasis is to be facilita-
ted, with local measures designed to help healing and 
minimize the risk of bleeding.
-Perioperative management in dental procedures with 
medium and high bleeding risk:
These cases (multiple extractions > 3, surgery lasting 
more than 45 minutes and head cancer surgery) require 
discontinuation of dabigatran and the need to consider 
subcutaneous heparin as an alternative treatment. There 
has been controversy for years regarding the suspension 
or alternation of anticoagulant therapy when planning 
invasive dental treatments. The instructions to discon-
tinue dabigatran should be consulted with the specialist 
physician (26-29). Table 2 provides guidance for discon-
tinuation of dabigatran.
Renal function (ClCr ml/min) Medium bleeding risk High bleeding risk
> 80 1 day before 2 days before
50 - 80 2 days before 3 days before
30 - 50 >48 hours 4 days before
<30 2-5 days before 5 days before
Table 2. Instructions to discontinue dabigatran in dental procedures with medium and high bleed-
ing risk.
-Postoperative management in dental procedures:
Management must be optimized from preoperative wor-
kup to the postoperative period in all patients subjected 
to oral anticoagulant treatment.
When to resume dabigatran depends on the extent to 
which the patient’s haemostasis is satisfactory. Treatment 
with dabigatran should be restarted as soon as possible. 
In dental procedures with average or high bleeding risk, 
dabigatran can be restarted 24-48 hours after surgery 
(30,31).
Local haemostatic measures such as sutures, gelatine or 
cellulose sponges, and tranexamic acid mouthwashes 
are required to help reduce the possibility of postopera-
tive bleeding. Good soft tissue management is essential 
in this sense, in order to avoid excessive traumatism of 
the surgical zone (32).
The management of haemorrhagic complications in pa-
tients under treatment with dabigatran should be indivi-
dualized according to the severity of the bleeding, the 
first step being to temporarily discontinue dabigatran. 
In cases of mild bleeding it is enough to stop the oral 
anticoagulant and use local haemostatic measures. In pa-
tients with renal insufficiency, the half-life of dabigatran 
can increase, which may worsen bleeding (33,34).
In moderate to serious bleeding it is essential to treat the 
patient in a hospital. Haemodialysis treatment, adminis-
tration of a transfusion of platelet concentrates, paren-
teral administration of antifibrinolytics or prothrombin 
complex concentrates or recombinant factor VIIa is es-
sential in cases of moderate to severe bleeding (35).
-Drug interactions:
Although dabigatran is not metabolized by the cytochro-
me P450 enzymes, it is a substrate of P-glycoprotein. 
This relationship defines the main interactions of dabi-
gatran with other drugs.  
While dabigatran does not interact directly with nonste-
roidal anti-inflammatory drugs (NSAIDs), these should 
be prescribed with caution. It is preferable to administer 
analgesics (36).
Pharmacodynamic interactions with other antithrombotic 
and antiplatelet agents have not been fully studied yet. The 
combined use of acetylsalicylic acid and dabigatran should 
be avoided, since it increases the risk of bleeding (37).
Proton pump inhibitors (omeprazole, esomeprazole, lan-
soprazole, rabeprazole, pantoprazole) slightly reduce the 
intestinal absorption of dabigatran (38).
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The use of erythromycin and clarithromycin should be 
avoided because of their interaction with the effect of 
dabigatran (39). This is also the case with rifampicin, 
which reduces dabigatran plasma concentrations (40).
Conclusions
The number of patients under treatment with new oral 
anticoagulants around us is increasing. 
Dabigatran is a valid alternative to vitamin K antago-
nists for oral anticoagulation in patients with nonvalvu-
lar atrial fibrillation.
Health professionals should be aware of the pharmaco-
kinetics and pharmacodynamics of new oral anticoagu-
lants, and it is necessary to establish clinical guidelines 
for the perioperative and postoperative management of 
dental patients being treated with these new drugs.
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